Pharma

The global peptide CDMO market hits $9B by 2036. How Bachem, PolyPeptide, and Lonza can build direct pipeline beyond GLP-1 anchor contracts.

The oligonucleotide market hits USD 5.42B in 2026 at 13.14% CAGR. How Swiss CDMOs like Bachem and Microsynth win therapeutic-grade contracts.

Swiss biologics CDMOs anchor a CHF 57.4B immunological export engine. How Lonza, Celonic and specialty players win clients beyond CPHI.

Swiss antibody-drug conjugate CDMOs sit on a market projected to hit $15.4B in 2026. Here is how Cerbios, Lonza, ADC Therapeutics and Araris compete.

The vaccine contract manufacturing market hits USD 5.24B in 2026. How Swiss fill-finish CDMOs win biologics and vaccine drug-product mandates.

Swiss pharma exports hit CHF 118.4B in 2025. Inside the API and fine-chemicals manufacturers building global pipeline as Europe reshores production.

The global mAb market hit $286B in 2025. Swiss manufacturers in Basel and Visp produce a large share. Here is how they build pipeline.

Swiss hormone and steroid exports under HS 2937 hit $971M in 2024, lifted by GLP-1 demand. How peptide CDMOs and steroid producers reach buyers.

France exported $9.53B of vaccines and biologicals in 2024. How French vaccine manufacturers reach global procurement buyers in 2026.

France produces 3.5B boxes of medicines a year, with one player holding 32% of generics. Here is how French generics makers reach international buyers.

France is set to launch 44 new cell and gene therapies by 2030. How French CDMOs win ATMP, CAR-T, and viral vector mandates from global sponsors.

Sanofi committed over EUR 2.5B to French biologics. How GTP Bioways, Cenexi and peers win mAb and biosimilar contracts beyond CPHI.

France runs 271 pharma plants and is Europe's #2 in biomedicines. Inside the French fill-finish CDMO field and how to reach drug-product buyers.